

Supplementary materials

Table S1. All agents considered as overactive bladder drugs.

Overactive bladder drugs
Darifenacin
Duloxetine
Flavoxate hydrochloride
Fesoterodine fumarate
Mirabegron
Oxybutynin hydrochloride
Proprantheline bromide
Solifenacin succinate
Tolterodine tartrate
Trospium chloride




Figure S1. Estimated values for proportion of mirabegron prescribing with and without the direct healthcare professional communication (DHPC), graphed by significant reduction in slope or level post-DHPC.